Check 35,000+ stocks against 26 valuation models and 37 quality factors

VICPLAS INTERNATIONAL LTD (569) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of VICPLAS INTERNATIONAL LTD S$0.06, price S$0.07, upside -8.7%, quality 50 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · SG · ISIN SG1G57870584

VI Thin data Sep 27, 2026

VICPLAS INTERNATIONAL LTD

569 · SG

Low PriorityFair Value upside is limited and quality is weak.

·Fair value 0.0630 SGD · Fairly valued (−8.7%)

!Quality 50/100

!Weak Growth (revenue 5y +5.0 %/yr)

!Loss-making · -4.7% net margin (TTM)

!Low debt · negative free cash flow

✓Ranks above peers (8/12)

!Narrow moat 2/100

!Evidence only low, so the estimate is less certain

!Weak on valuation: 22 out of 100

26 models, one by oneBear 0.0490 SGD to bull 0.0770 SGD Growth analysisrevenue history, year by year Quality 50/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch VICPLAS INTERNATIONAL LTD for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range 0.0670 SGD – 0.2500 SGD · fair‑value band 0.0490 SGD – 0.0770 SGD · the 0.0690 SGD price screens above the 0.0630 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow VICPLAS INTERNATIONAL in your weekly email

Every Wednesday you see whether VICPLAS INTERNATIONAL is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vicplas International Ltd, an investment holding company, engages in the medical devices, and pipes and pipe fittings businesses in Singapore, Malaysia, the People's Republic of China, the United Kingdom, and Mexico. The company manufactures, trades, and distributes piping systems for various industries, including waste and potable water systems for residential homes, schools, and commercial and industrial buildings; underground electrical and internal building wire piping systems; and data and signal line piping systems by telecommunications companies. It also designs, develops, manufactures, and assembles sterile and non-sterile medical devices. Vicplas International Ltd was founded in 1993 and is based in Singapore. Vicplas International Ltd is a subsidiary of Venner Capital S.A.

Stock analysis

VICPLAS INTERNATIONAL LTD (569) currently trades at 0.0690 SGD, while our model-based Fair Value estimate is 0.0630 SGD, so the stock looks roughly fairly valued today (gap 9.5%).

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 0.0490 SGD (bear) to 0.0770 SGD (bull), the price of 0.0690 SGD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

VICPLAS INTERNATIONAL LTD reported revenue of 102M SGD in FY2024 versus 88.8M SGD in FY2020, a compound +3.6%/yr. Reported net income was −1.4M SGD in FY2024.

Key figures

Market cap 35.3M SGD (≈ $27.5M) · P/S ratio 0.30 · EPS (TTM) −0.0100 SGD · Dividend yield 6.1% · Net margin −1.3% · Return on equity −8.4% · Return on assets (EBIT) 2.6% · Operating margin −3.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 31% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −9%, 569 screens richer than that median.

Fair Value models

Bear 0.0490 SGD Fair Value 0.0630 SGD Bull 0.0770 SGD

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

EV/EBITDA 0.0700 SGD 0.1000 SGD 0.1200 SGD 67

NCAV (Graham) 0.0700 SGD 0.1000 SGD 0.1500 SGD 53

All 2 models by family

Multiples

EV/EBITDA 0.0700 SGD 0.1000 SGD 0.1200 SGD 67

Asset-Based

NCAV (Graham) 0.0700 SGD 0.1000 SGD 0.1500 SGD 53

Open the full fair value analysis →

Notify me when 569 reaches fair value

Put 569 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 50/100

Of which business quality 53 · Market factors (momentum, volatility) 29

Profitability 34

Margins and returns on capital today

Quality Growth 36

Are margins and returns improving?

Cashflow 44

Earnings quality: real cash, not paper profit

Fin. Strength 52

Balance sheet, leverage, solvency risk

Investment 88

Disciplined investing over empire-building

Low Volatility 57

Calm price path (market factor)

Momentum 21

Price trend over the last 3–12 months (market factor)

52W Momentum 10

Distance to the 52-week high (market factor)

Net Issuance 82

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 9/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

−20.8%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−3.5%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+5.0%

Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+4.7%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

5.4% (2019) → −4.8% (2024)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss

not computed

Watch 569, get fair value alerts →

Compare VICPLAS INTERNATIONAL LTD with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 332 stocks

Beats the industry median on 8/11 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 53 · Above median

Fair Value upside −8.7% · Above median

Profitability

Return on assets −1.9% · Below median

Net margin (TTM) −4.7% · Below median

Operating margin (TTM) −3.1% · Below median

Growth and dividend

Revenue growth 13.1% · Above median

Dividend yield (TTM) 6.1% · Top 25%

Balance sheet

Debt / equity 0.01× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.37× · Cheapest 25%

P/S (TTM) 0.22× · Cheapest 25%

EV/EBITDA 10.2× · Cheaper than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)22 · sector 5

FUTURE (revenue growth)66 · sector 26

PAST (return on equity)0 · sector 12

HEALTH (low debt)100 · sector 97

DIVIDEND (yield)100 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Abbott Laboratories, ABT	$98.83	$74.79	−24%
Medtronic plc MDT	$87.09	$65.61	−25%
Stryker Corporation SYK	$278.77	$306.65	+10%
Boston Scientific Corporation BSX	$43.65	$48.02	+10%
Edwards Lifesciences Corporation EW	$86.29	$81.94	−5%
Siemens Healthineers AG SHL	€37.79	€35.19	−7%
DexCom, Inc DXCM	$86.68	$95.35	+10%
GE HealthCare Technologies Inc GEHC	$66.63	$70.37	+6%
Shenzhen Mindray Bio-Medical Electronics Co 300760	¥153.86	¥169.25	+10%
Koninklijke Philips N.V PHIA	€21.87	€15.23	−30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

VICPLAS INTERNATIONAL LTD · Fair Value
0.0630 SGD −9%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/569" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">VICPLAS INTERNATIONAL LTD · Fair Value</span><br><b style="font-size:20px">0.0630 SGD</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−9%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "VICPLAS INTERNATIONAL LTD Fair Value". https://www.fairvalue-calculator.com/stock/569

Frequently asked questions

Is VICPLAS INTERNATIONAL LTD (569) overvalued or undervalued?

As of Sep 27, 2026, our model estimates a fair value of 0.0630 SGD versus a price of 0.0690 SGD, about −9% upside (fairly valued).

What is the fair value of 569?

Our model-based fair value for VICPLAS INTERNATIONAL LTD is 0.0630 SGD (as of Sep 27, 2026), built from audited fundamentals. The current price: 0.0690 SGD.

What is the quality score of 569?

VICPLAS INTERNATIONAL LTD has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for VICPLAS INTERNATIONAL LTD (569)?

Our model-based price target is the fair value of 0.0630 SGD (as of Sep 27, 2026) from 2 valuation models. Cautious scenario 0.0490 SGD, optimistic scenario 0.0770 SGD. It is a calculation from audited fundamentals, not an analyst target.

What is the VICPLAS INTERNATIONAL LTD stock forecast for 2026?

Our models put fair value at 0.0630 SGD, about −9% upside versus a price of 0.0690 SGD (fairly valued). Cautious scenario 0.0490 SGD, optimistic scenario 0.0770 SGD. The calculation is refreshed regularly with new filings.

What is the revenue of VICPLAS INTERNATIONAL LTD (569)?

VICPLAS INTERNATIONAL LTD reported trailing-twelve-month revenue of about 128M SGD (latest available figure, as of Sep 27, 2026).

Does VICPLAS INTERNATIONAL LTD pay a dividend?

VICPLAS INTERNATIONAL LTD currently shows a dividend yield of about 6.08% relative to its recent price (as of Sep 27, 2026).

What is the intrinsic value of VICPLAS INTERNATIONAL LTD (569)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For VICPLAS INTERNATIONAL LTD it is 0.0630 SGD per share (as of Sep 27, 2026), against a price of 0.0690 SGD. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).

Is VICPLAS INTERNATIONAL LTD stock overvalued or undervalued in 2026?

As of Sep 27, 2026, 569 trades above its calculated fair value: price 0.0690 SGD, fair value 0.0630 SGD, a gap of about −9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 569?

No. The price is what the market pays today (0.0690 SGD); the fair value is what the company's own numbers justify (0.0630 SGD). For VICPLAS INTERNATIONAL LTD the two are 0.0060 SGD per share apart. That gap is exactly why we show both numbers side by side.

How much is VICPLAS INTERNATIONAL LTD worth?

The market values VICPLAS INTERNATIONAL LTD at about 35.3M SGD (market capitalisation, as of Sep 27, 2026). Per share that is 0.0690 SGD; our models calculate a fair value of 0.0630 SGD per share.

What do the bullish and bearish scenarios say about 569?

Our models span a range for VICPLAS INTERNATIONAL LTD: cautious scenario 0.0490 SGD, base 0.0630 SGD, optimistic 0.0770 SGD per share (as of Sep 27, 2026, price 0.0690 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of VICPLAS INTERNATIONAL LTD (569)?

Balance-sheet figures for VICPLAS INTERNATIONAL LTD (as of Sep 27, 2026): return on equity −8.4%, debt of 0.01 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.

How far is 569 from its 52-week high?

VICPLAS INTERNATIONAL LTD trades at 0.0690 SGD, about 31% below its 52-week high of 0.1000 SGD and 3% above the low of 0.0670 SGD (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0630 SGD is for.

Which stocks are comparable to VICPLAS INTERNATIONAL LTD?

From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is VICPLAS INTERNATIONAL LTD stock attractive at the current price?

The data as of Sep 27, 2026: price 0.0690 SGD, calculated fair value 0.0630 SGD (−9%), Quality Score 50/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 569 calculated?

We run VICPLAS INTERNATIONAL LTD through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.0630 SGD, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. VICPLAS INTERNATIONAL LTD itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of VICPLAS INTERNATIONAL LTD (569)?

The closing price on Oct 1, 2026 was 0.0690 SGD. Our model-based fair value is 0.0630 SGD, about −9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with VICPLAS INTERNATIONAL LTD right now?

The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of VICPLAS INTERNATIONAL LTD

How large is the market capitalisation of VICPLAS INTERNATIONAL LTD (569)?

The market capitalisation of VICPLAS INTERNATIONAL LTD is 35.3M SGD (≈ $27.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of VICPLAS INTERNATIONAL LTD (569)?

The price-to-sales ratio of VICPLAS INTERNATIONAL LTD is 0.30 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of VICPLAS INTERNATIONAL LTD (569)?

Earnings per share at VICPLAS INTERNATIONAL LTD are −0.0100 SGD. Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of VICPLAS INTERNATIONAL LTD (569)?

The dividend yield of VICPLAS INTERNATIONAL LTD is 6.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of VICPLAS INTERNATIONAL LTD (569)?

The net margin of VICPLAS INTERNATIONAL LTD is −1.3% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of VICPLAS INTERNATIONAL LTD (569)?

The return on equity (ROE) of VICPLAS INTERNATIONAL LTD is −8.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of VICPLAS INTERNATIONAL LTD (569)?

On an EBIT basis the return on assets of VICPLAS INTERNATIONAL LTD is 2.6% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of VICPLAS INTERNATIONAL LTD (569)?

The operating margin of VICPLAS INTERNATIONAL LTD is −3.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at VICPLAS INTERNATIONAL LTD (569)?

Revenue at VICPLAS INTERNATIONAL LTD is growing +13.1% versus a year earlier (3y avg −3.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at VICPLAS INTERNATIONAL LTD (569)?

Earnings per share at VICPLAS INTERNATIONAL LTD are growing +20.1% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does VICPLAS INTERNATIONAL LTD (569) generate?

The free cash flow of VICPLAS INTERNATIONAL LTD is −7.8M SGD (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does VICPLAS INTERNATIONAL LTD (569) carry?

The net debt of VICPLAS INTERNATIONAL LTD is 14.0M SGD (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch VICPLAS INTERNATIONAL LTD in the live analysis

One click puts VICPLAS INTERNATIONAL LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.